Germfree, an innovator in modular cleanroom infrastructure and services, and Orgenesis, an expert in decentralising cell and gene therapies, have revealed details of their recent cooperation.
The two companies have entered into an asset purchase and strategic partnership aimed at advancing Orgenesis’ therapeutic programmes, its suite of product development and GMP cell processing services.
The collaboration’s goal is to transform the production of cell and gene therapies, making these vital treatments more affordable and accessible to patients worldwide.
By combining Germfree’s expertise in designing, manufacturing, and maintaining advanced manufacturing facility environments with Orgenesis’ cutting-edge processes and analytical development capabilities, the partnership seeks to significantly reduce the production costs of cell and gene therapy products.
The ultimate goal is to enable broader adoption of life-saving treatments.
The partnership seeks to significantly reduce the production costs of cell and gene therapy products
Vered Caplan, CEO of Orgenesis, explained: “Under the agreement, Orgenesis and Germfree will join forces to co-market Orgenesis’ decentralised Octomera service platform, and its Octomera Mobile Processing Units and Labs (OMPULs) globally.
“The partnership marks a significant milestone in the bio-manufacturing industry, as the industry begins to pivot to the paradigm-shifting distributed processing of cell and gene therapies (CGTs),” Caplan continued.
Germfree will be marketing, manufacturing, and servicing OMPULs as part of its modular cleanroom fleet
“Germfree will be marketing, manufacturing, and servicing OMPULs as part of its modular cleanroom fleet, enabling Orgenesis to focus on its therapeutic pipeline with an emphasis on immuno-oncology. We are delighted to work with Germfree to meet the growing demand for our platform,” Caplan concluded.
Carol Houts, Chief Strategy Officer at Germfree, said: “The synergy between Germfree and Orgenesis paves the way for a future where regulatory collaboration and digital innovation ensure that life-saving therapies are developed and delivered with high efficiency and quality.”
